AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

GALECTIN THERAPEUTICS INC Director's Dealing 2013

Jun 21, 2013

33422_dirs_2013-06-21_9fbd05c8-9134-46a9-aae1-ba8644b65d43.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2013-06-19

Reporting Person: MCGAULEY THOMAS (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2013-06-19	Stock Option (Right to Buy)	$3.97	A	25000	Acquired	2023-06-19	Common Stock (25000)	Direct

Footnotes

F1: The options vest in full on the first business day following the date that the Issuer files its Form 10-Q for the quarter ended June 30, 2013.